Showing 1441-1450 of 3303 results for "".
Chemical Peels for Lip Augmentation
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/chemical-peels-for-lip-augmentation--dcwokite/19585/For patients looking for natural results or who want an alternative to hyaluronic acid fillers and needles, deep chemical peels are an excellent alternative for lip augmentation, explains Kachiu Lee, MD. She shares treatment pearls and discusses the kind of results patients can expect.Antibiotics and the Mutant Selection Window
https://practicaldermatology.com/topics/atopic-dermatitis/antibiotics-and-the-mutant-protection-window/19537/When considering antibiotics for treating acne, Hilary Baldwin, MD says there's a new concept dermatologists should consider in preventing antibiotic resistance. She describes the mutant selection window and why a higher dose antibiotic may actually be safer and more effective.The State of Dermatology Entrepreneurship 2015
https://practicaldermatology.com/topics/practice-management/the-state-of-dermatology-entrepreneurship-2015/18913/William Ju, MD, President of Advancing Innovation in Dermatology talks about entrepreneurship in dermatology. Where are new ideas, technologies, and therapies coming from, and how will they move ahead? Dr. Ju talks about the role of the pharmaceutical industry and finding resources.Heliocare in Practice
https://practicaldermatology.com/topics/practice-management/heliocare-in-practice/19220/Polypodium leucotomos extract, which is derived from a tropical fern, offers benefits to users by minimizing some of the damage to the skin caused by exposure to visible light—UVA and UVB radiation—as well as invisible infrared light. Vivian Bucay, MD, discusses its activity and its role as a dispenASDS Survey: 8 Million Procedures in 2012
https://practicaldermatology.com/topics/practice-management/asds-survey-8-million-procedures-in-2012/19259/"More and more people are seeking care from dermatologic surgeons." ASDS President Timothy Flynn, MD addresses new findings about the public's dependence on dermatologic surgeons. Derm surgeons' expertise and training in cosmetic and medical care are discussed.How Incyte Is Following the Science to Address Unmet Needs in Immune-Mediated Skin Conditions
https://practicaldermatology.com/topics/infections-infectious-disease/how-incyte-is-following-the-science-to-address-unmet-needs-in-immune-mediated-skin-conditions/19945/Ahmad Naim, MD, Vice President of US Medical Affairs at Incyte, shares how the company’s discovery expertise in immunology is fueling research aimed at delivering innovative medicines that address the unmet needs of people living with immune-mediated dermatologic conditions, including atopic dermatiSkin of Color Session: Dr. Harris
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/skin-of-color-session-dr-harris/32683/John E. Harris, MD, PhD, summarizes his vitiligo talk from the "Skin of Color Session" at Maui Derm 2025, during which he covered new therapeutic options for vitiligo as well as promising drugs in the pipeline and why they could be so impactful.New Drug Developments in Dermatology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/new-drug-developments-in-dermatology/19971/Despite the COVID pandemic, the FDA had a nearly record year in drug approvals, says Vinod Nambudiri, MD, MBA, which has translated to new developments in dermatology. He discusses approvals of tirbanibulin 1% ointment for actinic keratoses and clascoterone cream 1% for acne, and how they fit into tCOVID-19 Impact: Interrupted EBD Regimens
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/covid-19-impact-on-interrupted-ebd-regimens/19764/Aesthetic treatments aren't considered essential at this time, but what do you do about patients who were in the middle of a series of energy-based treatments? Eric Bernstein, MD says the good news is that the skin doesn't forget. Now is a great time to focus on topical therapies that complement in-Treatment Breaks for Super Responders: An Update from the GUIDE Study of Guselkumab in Psoriasis
https://practicaldermatology.com/topics/psoriasis/treatment-breaks-for-super-responders-an-update-from-the-guide-study-of-guselkumab-in-psoriasis/20222/Knut Schäkel, MD, a dermatologist at Heidelberg University Hospital in Germany, shares data on the withdrawal stage of the GUIDE study of guselkumab (Tremfya) in moderate-to-severe plaque psoriasis from his talk at the 2023 European Academy of Dermatology and Venereology meeting in Berlin.